



**BUPRENORPHINE**

**BUPE2021**

[www.bupe2021.com](http://www.bupe2021.com)

**SPONSORSHIP OPPORTUNITIES PROSPECTUS**

# Buprenorphine: Clinical and Public Policy Implications (BUPE2021)

Presented by: **Journal of Opioid Management (JOM)**

Date: **Thursday, December 16, 2021** [*The conference will be recorded and available online thru March 2022*]

Complementing our recently released special issue focused on all aspects of the use of buprenorphine in medicine, our goal is to broaden the knowledge base on buprenorphine, its potential in the healing pharmacopeia and as a pharmacological tool for pain management and/or addiction.

This unique online forum will be comprised of renowned specialists presenting the latest advances in basic science, neurology, clinical application, pharmacology, pharmacogenetics, public health, opioid addiction, ethics, legal, regulatory and compliance.



The image shows the cover of the Journal of Opioid Management, Volume 17, Number 7, Special Issue. The title is 'Buprenorphine: Clinical and Public Policy Implications'. The cover lists various articles and their authors, organized into sections like Editorials, Letter to the Editor, and Original Articles. The journal's subtitle is 'Basic Science, Clinical Pain Management, and Compliance'.

Journal of Opioid Management	
Basic Science, Clinical Pain Management, and Compliance	
Volume 17, Number 7	SPECIAL ISSUE
ISSN 1551-7489	
<b>Buprenorphine: Clinical and Public Policy Implications</b>	
CONTENTS	
EDITORIALS	
Alan Cowan: Buprenorphine from the bench to the bedside—Personal notes . . . . . 5	Saadet Inan, MD, PhD; Michael Guarnieri, PhD, MPH
Buprenorphine not a silver bullet but an opioid of choice for chronic pain . . . . . 11	Melhar P. Davis, MD, FCCP, FAAHPM; Jeffrey Fudin, PharmD, FACC, FASHP, FFSMB
LETTER TO THE EDITOR	
Buprenorphine: Not a silver bullet, and still controversial . . . . . 9	Sudheer Pora, DO, FASAM; Michael Sprintz, DO, DFASAM; Anje M. Barrevel, MD; Lynn Kohan, MD
ORIGINAL ARTICLES	
Buprenorphine blood concentrations: A biomarker for analgesia . . . . . 15	Michael Guarnieri, PhD, MPH
Emerging pharmacologic mechanisms of buprenorphine to explain experience of analgesia versus adverse effects . . . . . 21	Jeffrey Bettinger, PharmD; Himayapsill Batista Quevedo, PharmD; Jacqueline Cleary, PharmD, BCACP
Perioperative pain management and outcomes in patients who discontinued or continued pre-existing buprenorphine therapy . . . . . 33	Aamer Altaar, PharmD, BCPS; Molly Curran, PharmD, BCPS, BCCCP; Lyndsi Meyenburg, PharmD, BCPS; Richard Botmer, DHA, PA-C; Clarissa Johnston, MD; Kirsten Roberts Mason, PharmD, BCPS
A history of opioid abuse: Why buprenorphine is superior for the management of opioid use disorder and pain . . . . . 43	Michael D. Kenrowski, MS; Nitin K. Sekhri, MD
Dispensing of medications used in MAT for Medicare Part D beneficiaries: Impact of 2016 CARA . . . . . 51	Chris Gillette, PhD; Catherine Shall, PA-C, MPAS; Sarah J. Garvick, MS, MPAS, PA-C; Lindsey Mitchell, MSM, MMS, PA-C; Julienne Kirk, PharmD
Interest in long-acting injectable buprenorphine among syringe services program participants . . . . . 59	Hannah Epstein, BS; Andres Perez-Correa, MD; Jason Beltre, BS; Christine Fitzsimmons, ASN; Pia Marcus, BA; Franklin Ramirez, BA; L. Synn Stern, RN, MPH; Brianna L. Norton, DO, MPH; Aaron D. Fox, MD, MS; Andrea Jakubowski, MD, MS
Buprenorphine not detected on urine drug screening in supervised treatment . . . . . 69	Nazila Jamshidi, MBBS, FRACP, FACHAM, BPharm (Hons), PhD; Aishay Athavale, MBBS, FRACP, BPharm (Hons), MMed; Bridin Murnion, MBChB, FRACP, FFPANZCA, FACHAM
Patient satisfaction with clinic-based medication pick up: Addressing pharmacy-level challenges to buprenorphine access . . . . . 77	Elizabeth Kolb, MS; Mark Rueth, PharmD
TOC continued over	

# We invite you to become a commercial supporter of BUPE2021.

As a commercial supporter you can enjoy a wide range of benefits from a carefully selected sponsorship.

Your sponsorship helps support valuable education and networking throughout the **BUPE2021** conference and beyond.

## Benefits of Participating...

- Extended Brand Exposure; Showcase your products or services thru March 2022
- Reach a diverse, multidisciplinary audience
- Raise brand awareness and create preference
- Support a sales promotion campaign
- Create positive PR and raise awareness of your organization as a whole

This prospectus provides an overview of the opportunities available at **BUPE2021** to support important professional education, and how to reap substantial marketing benefits for several months.

# SPONSORSHIP OPPORTUNITIES

Sponsorship is an ideal way to gain prime, credible exposure and make a long-term impact among a highly influential audience.

Sponsors stand out and deliver a message of commitment and support to attendees.

## **PLATINUM SPONSOR PACKAGE \$17,500**

- Premium spot in the online conference website expo section - includes link to your company website/landing page, social channel links  
*[Minimum 4 months thru March 2022]*
- Recognition in pre- and post-conference email blasts
- Rotating banner ad on BUPE2021 homepage
- Verbal Recognition at the opening general session
- One (1) custom email broadcast to the full conference list post-conference (10,000+ database)
- Attendee roster with names and email addresses

# SPONSORSHIP OPPORTUNITIES

As a **BUPE2021** sponsor your organization is poised to reap many benefits from contact with those most prone to use your products or services.

The levels of participation are designed specifically to meet your marketing goals.

## **GOLD SPONSOR PACKAGE \$10,000**

- Premium spot in the online conference website expo section - includes link to your company website/landing page, social channel links  
*[Minimum 4 months thru March 2022]*
- Recognition in pre- and post-conference email blasts
- Verbal Recognition at the opening general session
- Attendee roster with names and email addresses

# SPONSORSHIP OPPORTUNITIES



## **SILVER EXHIBIT PACKAGE \$2,500**

- Spot in the online conference website expo section - includes 100-word company description and link to your company website/landing page, social channel links [*Minimum 4 months thru March 2022*]
  - Verbal Recognition at the opening general session
  - Attendee roster with names and email addresses
- 
- You're bound to make new connections, meet unexpected partners and maximize your marketing dollars.

[CLICK HERE for Sponsor Opportunities Application Form](#)

## YOUR OPPORTUNITY IS HERE...

### **EXTENDED REACH**

We offer an array of sponsorship opportunities to fit your needs and budget. Among them are:

- **Website Advertising**

Place your ad directly in front of organized medical professionals each time they visit the BUPE2021 or JOM websites.

- **Mailing List Program**

Send a mail piece or email message directly to JOM's 10,000+ database through this exclusive mailing list program.

### Connect with Market Leaders

Partnering with BUPE2021 and the *Journal of Opioid Management* connects you to more than 10,000 medical professionals who are the unique audience that can help you break into or cement your status as a leader in the pain management and OUD specialties.

Reach the influential gatekeepers to the physician market you're looking to tap into.

# YOUR OPPORTUNITY IS HERE...

## MISSION STATEMENT

**Buprenorphine: Clinical and Public Policy Implications (BUPE2021)** addresses all aspects of the proper use and safe management of buprenorphine by providing education and guidance to physicians and healthcare professionals on how to safely prescribe and responsibly manage this and other opioids, as well as the legal and ethical ramifications each medical professional must face.

The ***Journal of Opioid Management*** is the only peer-reviewed professional journal dedicated to all aspects of the proper and adequate use of opioids. It provides education and guidance to physicians and healthcare professionals on how to safely prescribe and responsibly manage these powerful drugs.

Copyright 2021-2022 Weston Medical Publishing, LLC All Rights Reserved

If you have any questions, or need additional information, we are happy to assist.

Please contact us at:

781-899-2702 ext. 107 or ext. 108

Richard A. DeVito, Jr., Publisher

Journal of Opioid Management

radjr@pnpc.com

Michael J. Glynn, Conference Director

BUPE2021

michael\_glynn@pnpc.com



# BUPE2021

**Buprenorphine:  
Clinical and Public Policy Implications (BUPE2021)**

*An Online Conference*

**December 16, 2021**

**COMPLETE AND RETURN THIS FORM TO:**

email: michael\_glynn@pnpco.com, or

mail to: Journal of Opioid Management  
470 Boston Post Rd, Suite 301  
Weston, MA 02493

**SPONSOR OPPORTUNITIES APPLICATION FORM**

( ) Yes, I will take advantage of the following marketing opportunity available at the **BUPE2021** an online conference being presented on Thursday, December 16, 2021.

MARKETING/EXHIBITOR LEVEL:

PLATINUM LEVEL \$ \_\_\_\_\_  OTHER \$ \_\_\_\_\_

GOLD LEVEL \$ \_\_\_\_\_ DETAIL \_\_\_\_\_

SILVER LEVEL \$ \_\_\_\_\_

TOTAL INVESTMENT \$ \_\_\_\_\_

Company Name \_\_\_\_\_

Address \_\_\_\_\_

City \_\_\_\_\_ State/Province \_\_\_\_\_ Zip/Postal Code \_\_\_\_\_

Phone \_\_\_\_\_ Fax \_\_\_\_\_ Website \_\_\_\_\_

Signature of authorizing person \_\_\_\_\_

Printed name of person authorizing \_\_\_\_\_

Title \_\_\_\_\_

PO # \_\_\_\_\_ E-mail \_\_\_\_\_

PAYMENT:

Make checks payable to: WESTON MEDICAL PUBLISHING, LLC 470 Boston Post Rd, Suite 301, Weston, MA 02493, USA

Credit Card: Account # \_\_\_\_\_ Exp. Date \_\_\_\_\_ CCV \_\_\_\_\_

Advertising Contact Name: \_\_\_\_\_ Phone: \_\_\_\_\_

Exhibit Contact Name: \_\_\_\_\_ Phone: \_\_\_\_\_

Bill to (if different from above): \_\_\_\_\_

Name of institution \_\_\_\_\_

Address \_\_\_\_\_

City \_\_\_\_\_ State/Province \_\_\_\_\_ Zip/Postal Code \_\_\_\_\_

Phone \_\_\_\_\_ Fax \_\_\_\_\_ Email: \_\_\_\_\_

Terms: All marketing and exhibitor support must be prepaid. The program materials must be submitted 15 days before the conference date. Exhibitors and marketing will be issued an invoice after signing this contract. Payment is due upon receipt of invoice and no later than 10 days prior to the conference date. All other ICOP Terms & Conditions apply. Buprenorphine: Clinical and Public Policy Implications and BUPE2021 are trademarks of Weston Medical Publishing LLC. Journal of Opioid Management is a registered trademark of Weston Medical Publishing LLC.